SLC5A2 and type 2 diabetes mellitus: Eligible participants were 20 years of age or older with inadequately controlled T2DM (HbA 1c ≥ 7.0% to <11.0%) and were receiving oral antihyperglycemic monotherapy (sulfonylurea, biguanides, α-glucosidase inhibitors, thiazolidinedione, glinides, or SGLT2 inhibitors) for at least three months.